Revenue Recognition - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Revenue Recognition Milestone Method [Line Items]
Revenue recognition cash discount percentage	2.30%		2.30%
Provision for chargebacks and other deductions included as reduction of accounts receivable total	$ 28,331,000		$ 28,331,000		$ 22,868,000
Upfront fees			2,000,000.0
Commercial Platform
Revenue Recognition Milestone Method [Line Items]
Provision for chargebacks and other deductions included as reduction of accounts receivable total	28,331,000		28,331,000		$ 22,868,000
Chargebacks and other revenue deductions expense	52,400,000	$ 38,800,000	133,300,000	$ 91,300,000
Licensed IP
Revenue Recognition Milestone Method [Line Items]
Revenue recognized	1,600,000	0	6,700,000	0
Licensed IP | 2017 Almirall Out-License Arrangement in U.S.
Revenue Recognition Milestone Method [Line Items]
Revenue recognized upon achievement of development milestone			5,000,000.0
Licensed IP | 2011 PharmaEssentia License Agreement
Revenue Recognition Milestone Method [Line Items]
Revenue recognized upon achievement of development milestone			1,600,000
Royalty revenue
Revenue Recognition Milestone Method [Line Items]
Royalty revenue related to sales	$ 400,000	100,000	1,600,000	300,000
Transferred at a Point in Time | Licensed IP
Revenue Recognition Milestone Method [Line Items]
Revenue recognized		$ 5,100,000	0	26,100,000
Revenue recognized upon achievement of first commercial milestone			500,000
Transferred at a Point in Time | Licensed IP | 2017 Almirall Out-License Arrangement in U.S.
Revenue Recognition Milestone Method [Line Items]
Revenue recognized upon achievement of first commercial milestone			$ 20,000,000.0
Transferred at a Point in Time | Licensed IP | 2017 Almirall Out-License Arrangement in Europe
Revenue Recognition Milestone Method [Line Items]
Revenue recognized upon achievement of first commercial milestone				$ 5,000,000.0